Every material Form 8-K Hemab Therapeutics Holdings, Inc. has filed with the SEC since May 21, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Hemab Therapeutics' board elected Keli Walbert as a director effective September 24, 2026, and also appointed her to the Audit Committee. The filing describes standard non-employee director pay, including an option for 36,000 shares and $40,000 in annual board cash compensation, which is typical for a board addition and has limited direct effect on shareholders.
Keli Walbert elected to the board effective September 24, 2026, as a Class I director with a term expiring at the 2027 annual meeting.
Walbert also joins the Audit Committee.
Director pay includes an option to purchase 36,000 shares at the closing price on the grant date, vesting monthly over three years.
Annual cash compensation is $40,000 for board service plus $10,000 for Audit Committee service.
Hemab Therapeutics reported second quarter 2026 results, with a net loss of $24.2 million, or $0.80 per share, up from $12.2 million in the year-earlier quarter. Research and development and general and administrative expenses both rose, and the company says its cash will fund operations into 2029 after its May 2026 initial public offering. The filing gives no revenue or guidance figures, and the lower per-share loss mainly reflects a much larger share count.
Net loss was $24.2 million, or $0.80 per share, for the quarter ended June 30, 2026, versus $12.2 million, or $12.91 per share, a year earlier.
Research and development expenses were $20.3 million, compared with $12.9 million a year earlier; general and administrative expenses were $5.7 million, compared with $3.2 million.
Cash, cash equivalents and marketable securities totaled $457.5 million at June 30, 2026, including net IPO proceeds of $317.2 million; the company expects this to fund operations into 2029.
Hemab Therapeutics reported a first quarter 2026 net loss of $22.7 million, or $23.98 per share, up from $15.3 million, or $16.18 per share, a year earlier, as research and development spending rose. The company completed an upsized IPO in May 2026 at $18.00 per share, raising gross proceeds of $346.7 million, and says its cash and the expected net proceeds of about $317.2 million will fund operations into 2029.
Q1 2026 net loss was $22.7 million, or $23.98 per share, versus $15.3 million, or $16.18 per share, in Q1 2025
Research and development expenses rose to $19.5 million from $14.1 million; general and administrative expenses rose to $4.2 million from $2.5 million
Cash, cash equivalents and marketable securities were $163.5 million at March 31, 2026, down from $185.5 million at December 31, 2025
IPO of 19,262,500 shares at $18.00 per share raised gross proceeds of $346.7 million; common stock began trading on Nasdaq as COAG
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Hemab Therapeutics Holdings, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →